Paul Workman is Chief Executive and President of The Institute of Cancer Research (ICR), London. He is also Harrap Professor of Pharmacology and Therapeutics and formerly (1997-2016) Director of the CRUK Cancer Therapeutics Unit at ICR. Under his leadership, the Unit identified 20 clinical drug candidates and progressed 10 into Phase I clinical trials. Paul serves as Director of the CRUK Centre at the ICR/Royal Marsden Hospital and founding Director of the CRUK Convergence Science Centre at ICR and Imperial College. Paul previously held academic positions at Leeds University, MRC Clinical Oncology Unit/Cambridge University, Stanford University, and CRUK Beatson Laboratories/Glasgow University. In his pharma and biotech career, Paul was head of the cancer biology section at AstraZeneca (1993-97), a scientific founder of Piramed Pharma (acquired by Roche) and of Chroma Therapeutics, and is a Science Partner at Nextech. He is a Non-Executive Director of the Royal Marsden, Director of the non-profit Chemical Probes Portal and an adviser to other academic and commercial organizations. In his personal science, Paul is a leader in the discovery of innovative molecularly targeted cancer drugs and chemical probes, including inhibitors of PI3 kinase, AKT, CDKs, HSP90 and the HSF1 pathway. He has a major interest in the molecular mode of action of, and resistance to, precision medicine cancer drugs, and he is the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development. Paul has published >550 research articles receiving >40,000 citations and has an h-index of 105. Paul is an elected Fellow of the Royal Society, Academy of Medical Sciences, Royal Society of Chemistry, Royal Society of Medicine, Royal Society of Biology, and European Academy of Cancer Sciences and he is a Cancer Research UK Life Fellow. Paul has received numerous awards, including leadership of the ICR/Royal Marsden Team that won the prestigious American Association for Cancer Research Team Science Award in 2012, recipient of the CRUK Translational Cancer Research Prize (2013) and the Queen’s Anniversary Prize (to ICR) in 2017. Paul is a Deputy Editor of Molecular Cancer Therapeutics, a Reviews Editor of Cancer Cell and serves on the editorial boards of numerous journals. He writes talks and blogs about cancer research, drug discovery and chemical probes.
« Go Back